Application

GW4064 has been used:to investigate its ability to protect the livers of mice from lipopolysaccharide (LPS)-induced inflammation and apoptosisto examine its capability to inhibit mucosal injury in ileum caused by lipopolysaccharide (LPS)to treat ileal explants

Biochem/physiol Actions

GW4064 is a FXR agonist. GW4064 is a potent (EC50 = 15 nM), non-steroidal agonist of the orphan nuclear receptor FXR. It shows no activity on other nuclear receptors including RAR up to 1 mM. This is an important tool for the study of the involvment of FXR in a variety of biological activities.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

GW4064 is a synthetic isoxazole, which is used to decipher the cellular and physiological functions of farnesoid X receptor (FXR). It is an estrogen receptor-related receptors (ERRs) agonist.

Packaging

5, 25 mg in glass bottle